Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

847 results about "Asthma" patented technology

A condition in which the airways (the tubes that carry air in and out of the lungs) narrow and swell causing reversible obstruction.

Small sample respiratory disease pattern recognition method based on diffusion model

PendingCN119811684AMedical data miningHealth-index calculationObstructive ApneaData set
The invention provides a small sample respiratory disease pattern recognition method based on a diffusion model. The method comprises the following steps: firstly, for common respiratory disease types, collecting and classifying data of three respiratory modes: normal respiration, pause respiration and deep respiration which respectively correspond to respiratory diseases such as normal respiration, obstructive apnea and asthma in medicine; secondly, learning an internal distribution rule of data by using a radio frequency diffusion model, and generating diversified and high-quality radio frequency time sequence data on the basis of limited real samples so as to expand a data set; and thirdly, combining the generated data with real data, extracting an accurate respiration signal through a one-dimensional time sequence extraction algorithm, and converting a time sequence into a two-dimensional image by utilizing a Gramian Angle Field (GAF) method, so that the time dependency relationship of the time sequence is intuitively presented in the image. And finally, a convolutional neural network (CNN)-Transform deep learning model is adopted to carry out feature extraction and classification on the image data, and then multi-scale feature analysis and breathing mode recognition are carried out. According to the method, the recognition precision and generalization ability of the model are remarkably improved under the small sample condition, and an accurate and reliable solution is provided for non-contact breathing mode recognition.
Owner:CHONGQING UNIV OF POSTS & TELECOMM

Chemical ablation and method of treatment for various diseases

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.
Owner:NEUROTRONIC INC

Chemical ablation and method of treatment for various diseases

To provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue.SOLUTION: In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective in injuring or damaging tissue, nerves and nerve endings in order to relieve disease symptoms.SELECTED DRAWING: Figure 3B
Owner:NEUROTRONIC INC

Chemical ablation formulations and methods of treatments for various diseases

To provide formulations for treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease.SOLUTION: The invention provides a chemical formulation for use in a method of treating a disease, the method comprising: inserting a delivery catheter into a vascular lumen adjacent to nerves, where the vascular lumen includes a pulmonary artery; infusing the chemical formulation into the vascular lumen through the delivery catheter, where the amount of the chemical formulation is an amount effective to injure or damage the nerves and provide benefits in alleviating the symptoms of the disease; and withdrawing the delivery catheter from the blood vessel. The chemical formulation is at least one of 10-100 wt.% of ethanol, and 1-100 wt.% of acetic acid. The disease includes pulmonary arterial hypertension.SELECTED DRAWING: None
Owner:NEUROTRONIC INC

Mixture of HMOS and b. infantis

The invention provides a composition for use in preventing and / or treating a viral infection in a subject, wherein the composition comprises Bifidobacterium longum subsp. infantis and a HMO mixture consisting of 2'-fucosyllactose (2FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyllactose (6SL), 3'-sialyllactose (3SL), and lacto-N-neotetraose (LNnT), and optionally 3-fucosyllactose (3FL). The invention also provides the composition for use in preventing and / or reducing the risk of allergen sensitisation, preventing and / or reducing the risk of developing a respiratory condition in a subject, and / or preventing and / or reducing the risk of developing asthma in a subject.
Owner:SOCIETE DES PRODUITS NESTLE SA

Chemical ablation formulations and methods of treatments for various diseases

Embodiments of the present invention are directed to the treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease by delivering of an effective amount of formulations at desired temperature to target tissue. The formulations include gases, vapors, liquids, solutions, emulsions and suspensions of one or more ingredients. The temperature may enhance safety and efficacy of the formulations for the treatments. The amounts of the formulation and / or energy are effective to injury or damage the tissues to have a benefit of symptom relive.
Owner:NEUROTRONIC INC

Mongolian medicine tea drink capable of relieving respiratory system abnormality and preparation method and application of Mongolian medicine tea drink

The invention relates to the technical field of traditional Chinese medicine, in particular to a Mongolian medicine tea drink for relieving respiratory system abnormality and a preparation method and application thereof.The Mongolian medicine tea drink is prepared from rhododendron micranthum, pomegranate, amomum cardamomum, long pepper, cinnamon, safflower, agilawood, clove, myristica fragrans, fructus choerospondiatis, bistort rhizome, liquorice, tabasheer, radix aucklandiae, white raisin and crabs. The processed products of the Mongolian medicine components are weighed according to the formula dosage, then ground into coarse powder and bagged to prepare tea bags. The Mongolian medicine tea drink provided by the invention has the effects of moving Heli, relieving cough, reducing phlegm and diminishing swelling; the traditional Chinese medicine composition can be used for treating the symptoms such as' Bada dry Hiri 'dizziness, asthma, chronic bronchitis, indigestion disease, edema, edema and water tympanites.
Owner:INNER MONGOLIA MEDICAL UNIV

Mixture of HMOS and b. infantis

The invention provides a composition for use in preventing and / or treating a viral infection in a subject, wherein the composition comprises Bifidobacterium longum subsp. infantis and a HMO mixture consisting of 2'-fucosyllactose (2FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyllactose (6SL), 3'-sialyllactose (3SL), and 3-fucosyllactose (3FL). The invention also provides the composition for use in preventing and / or reducing the risk of allergen sensitisation, preventing and / or reducing the risk of developing a respiratory condition in a subject, and / or preventing and / or reducing the risk of developing asthma in a subject.
Owner:SOCIETE DES PRODUITS NESTLE SA

Antibodies that bind TSLP and methods of use

Described herein are novel and improved antibodies that bind to thymic stromal lymphopoietin (TSLP) and methods of use thereof. In certain aspects, described herein are methods of inhibiting TSLP biological activity. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of TSLP. In certain aspects, described herein are methods of treating asthma by administering anti-TSLP antibodies.
Owner:PARAGON THERAPEUTICS INC

Method for constructing prediction model of pan-apoptosis related biomarkers of asthma based on convolutional neural network algorithm and application

The invention discloses a method for constructing a prediction model of pan-apoptosis related biomarkers of asthma based on a convolutional neural network algorithm and application, and the method comprises the steps: firstly obtaining related data from a database, and determining characteristic pan-apoptosis related genes PDGs in asthma through an SVM support vector machine, LASSO regression analysis and RF random forest regression; the method comprises the following steps: establishing an lncRNA-miRNA-mRNA network by using interaction STRING and Cytoscape software, constructing a prediction model of the pan-apoptosis related biomarkers of asthma through a convolutional neural network, and analyzing the diagnosis accuracy of potential target genes through an ROC curve. 10 characteristic PDGs playing an important role in asthma are finally obtained, the difference of the genes between a normal group and an asthma group is proved, and the enrichment pathway and immune cell infiltration of the genes have a certain relation with the occurrence and development of asthma, so that a prediction model of the pan-apoptosis related biomarkers of asthma is constructed, and the prediction model is used for predicting the pan-apoptosis related biomarkers of asthma. And a new research direction is provided for studying the pathogenesis and treatment of asthma.
Owner:THE SECOND AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIV +1

Method for analyzing cough sound by using disease characteristics to diagnose respiratory diseases

The invention relates to the field of biological medicine, and discloses a method and system for analyzing cough sound by using disease characteristics to diagnose respiratory diseases, and the method comprises the steps: deploying a six-microphone annular array to achieve the precise positioning and triggering of a sound source; self-adaptive spectral subtraction and Wiener filtering cascade are adopted to enhance the audio; segmenting a cough segment based on energy envelope; fusing the Mel-cepstrum, the linear prediction residual error, the harmonic energy ratio and the transient zero-crossing rate to construct a pathological feature matrix; extracting local, medium-range and global time sequence features through a three-branch parallel convolutional network; inputting a disease specific classifier to discriminate asthma, pneumonia and laryngitis respectively, and applying a feature decoupling regular term to improve interpretability. The system correspondingly realizes the modularized processing flow. According to the method, the cough sound collection quality and the disease subtype recognition accuracy in a complex environment are improved, meanwhile, the thermodynamic diagram is output to assist clinical decision making, and the diagnosis credibility and practicability are enhanced.
Owner:HUZHOU CENT HOSPITAL

Methods, apparatuses, and systems for the treatment of pulmonary disorders

ActiveUS20250064510A1ElectrotherapySurgical instruments for heatingDiseaseAcute bronchitis
Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.
Owner:GALVANIZE THERAPEUTICS INC

Patch for treating cough and asthma and preparation process thereof

The invention belongs to the technical field of traditional Chinese medicine patches, mainly relates to a traditional Chinese medicine patch and a preparation method thereof, and in particular relates to a patch for treating cough and asthma and a preparation process thereof. Natural plants including the semen brassicae, the pink reineckea herb and the modified herba ephedrae are selected, the performance is improved through synergistic fermentation of the lactobacillus acidophilus CICC-22162 and the bifidobacterium breve CICC-6184, the effect of treating cough and asthma of the traditional Chinese medicine is improved, meanwhile, under the fermentation condition, the effect of treating diarrhea is achieved under the synergistic effect of leavening of the semen brassicae and the pink reineckea herb, and the traditional Chinese medicine composition has a good application prospect. In addition, the perillaseed extracting solution and the asarum extracting solution which are used in the patch have extremely high oxidation resistance under the synergistic effect, so that the stability of the patch is effectively improved, and the shelf life of the patch is prolonged.
Owner:GUIZHOU KANGQI PHARM EQUIP CO LTD

Antibody capable of binding to thymic stromal lymphopoietin and use thereof

Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody of the light chain and heavy chain variable regions of the anti-TSLP antibody and antigen-binding fragments thereof, or a pharmaceutically acceptable salt or solvent compound thereof, and the use thereof as a medicament for treating asthma, especially the use thereof in the preparation of a drug for treating TSLP-positive diseases or conditions.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1

Chimeric antigen receptors (CARs), compositions and methods thereof

The present disclosure provides chimeric antigen receptors, compostions, and methods thereof. In one embodiment the present disclosure provides a method of treating autoimmune diseases, asthma, and preventing or mediating organ rejection in a subject.
Owner:ICELL GENE THERAPEUTICS LLC

Method of quantifying lung disease

A method of using computed tomographic (CT) image data to provide a quantitative assessment of various classes of lung disease, including for example, interstitial lung abnormalities associated with interstitial lung disease (ILD) represented as a mass contribution, or as a percentage contribution by mass. Mass fractions of emphysema due to COPD are also addressed along with the special case of addressing air trapping mass fraction due to ILA / ILD, asthma, COPD, BOS.
Owner:VIDA DIAGNOSTICS

Methods, apparatuses, and systems for the treatment of pulmonary disorders

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.
Owner:GALVANIZE THERAPEUTICS INC

Double stranded oligonucleotide for modulating JAK1 expression

The present invention relates to double stranded oligonucleotides that are complementary to JAK1, leading to modulation of the expression of JAK1. Modulation of JAK1 expression is beneficial for a range of medical disorders including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. Also included are compositions comprising the double stranded oligonucleotide and methods of treatment using the double stranded oligonucleotide.
Owner:F HOFFMANN LA ROCHE & CO AG +1

Lactobacillus reuteri and application of lactobacillus reuteri in preparation of products for relieving lung diseases

The invention discloses lactobacillus reuteri and application thereof in preparation of products for relieving lung diseases, and the lactobacillus reuteri MLR1103 has the preservation number of CGMCC No.31162. Experiments prove that the lactobacillus reuteri or bacterial powder containing the lactobacillus reuteri has the characteristics of tolerance to gastric acid, intestinal juice and cholate, and can be applied to preparation of products for relieving lung diseases. Acute lung injury caused by mouse LPS, lung injury caused by PM2.5, pulmonary fibrosis, asthma, pneumoconiosis and cough symptoms can be remarkably relieved, lung pathological changes are relieved, and lung functions are recovered.
Owner:DALIAN WANRUIKANG BIOTECHNOLOGY CO LTD

Inverse agonists of RAR related orphan receptors (RORS)

The invention relates to the use of a ROR inverse agonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for modulating RORs and / or controlling autoimmune diseases and antibody mediated rejection in a patient. The RORs mediated disease or autoimmune disease includes HIV, cancer, celiac disease, diabetes mellitus type 1, Graves' disease, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease, cardiovascular disease, inflammatory diseases, neurological disorder, multiple sclerosis, acute respiratory distress syndrome and arteriosclerosis.
Owner:11949098 CANADA INC

Method and apparatus for treatment of pulmonary conditions

Apparatus and methods for deactivating bronchial nerves and ablating smooth muscle extending along a bronchial branch of a mammalian subject to treat asthma and related conditions. An ultrasonic transducer (11) is inserted into the bronchus as, for example, by advancing the distal end of a catheter (10) bearing the transducer into the bronchial section to be treated. The ultrasonic transducer emits ultrasound so as to heat tissues throughout a relatively large impact volume (13) to a temperature sufficient to inactivate nerve conduction and ablate smooth muscle but insufficient to cause rapid ablation or necrosis of the surrounding tissues. The treatment can be performed without locating or focusing on individual bronchial nerves or smooth muscle.
Owner:AERWAVE MEDICAL INC

Methods for treating exacerbation of inflammatory respiratory diseases

To provide: therapeutic methods for the treatment of exacerbation of inflammatory respiratory diseases, including chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and asthma; in particular, methods for patient selection, diagnosis and treatment; and methods for preparing and analyzing lysophosphatidic acid (LPA) samples.SOLUTION: The level of one or more of lysophosphatidic acid (LPA) 16:0, LPA18:0, LPA18:1, LPA18:2 and LPA20:4 in a sample from a patient is measured.SELECTED DRAWING: None
Owner:GENENTECH INC +1

Methods of administering antibodies that bind interleukin 4 receptor alpha

Described herein are antibodies that bind Interleukin 4 Receptor alpha (IL-4Rα) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-4Rα biological activity. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL-4 and / or IgE. In certain aspects, described herein are methods of treating asthma by administering anti-IL4Rα antibodies.
Owner:APOGEE THERAPEUTICS INC

Anti-canine IL-31 antibody and application thereof

The invention relates to an anti-canine IL-31 antibody or an antigen binding part thereof and application thereof, and belongs to the technical field of antibody preparation. The invention relates to an anti-canine interleukin-31 antibody or an antigen binding part thereof, amino acid for coding the antibody or the antigen binding part thereof, polynucleotide, a carrier containing the polynucleotide, a host cell containing the polynucleotide or the carrier, a method for preparing and purifying the antibody and application of the antibody or the antigen binding part thereof. The anti-canine IL-31 antibody disclosed by the invention can be specifically combined with a canine IL-31 antigen, and can effectively relieve symptoms such as pruritus, allergy, nasal polyp or asthma and the like. The mutated anti-canine IL-31 antibody also has a corresponding function of combining with the antigen canine IL-31, and also can be used for treating IL-31 related diseases.
Owner:GUANGZHOU YUANBO MEDICAL TECH CO LTD

A cough-relieving and asthma-relieving traditional Chinese medicine composition, a preparation method thereof and application thereof

The present application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for relieving cough and asthma, and a preparation method and application thereof. The traditional Chinese medicine composition comprises, in mass parts, perilla seed 5-15 parts, radish seed 5-15 parts, white mulberry bark 5-15 parts, orange red or processed orange red 5-15 parts, and cassia 5-15 parts. The traditional Chinese medicine composition has the effect of relieving cough and asthma, can effectively improve the clinical symptoms such as cough, expectoration and wheezing of patients with chronic obstructive pulmonary disease, promote lung rehabilitation, improve the dyspnea condition of the patients, and improve the life quality of the patients.
Owner:GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE

Aldose reductase inhibitors and methods of use thereof

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, asthma, and the like.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Children cough variant asthma diagnosis system based on decision tree

The invention discloses a children cough variant asthma diagnosis system based on a decision tree, and relates to the technical field of asthma diagnosis, the children cough variant asthma diagnosis system comprises a diagnosis management platform, the diagnosis management platform is in communication connection with a data acquisition module, a diagnosis model construction module, a diagnosis reasoning module and an intervention suggestion module, and the modules are in electric signal connection; the data acquisition module is used for collecting and preprocessing child patient clinical data including symptoms, signs, medical history and multi-dimensional examination data. By integrating the multi-dimensional examination data and the medical history, symptom change trend and family history information of the child patient, the condition of the child patient can be comprehensively and deeply analyzed, reasoning and judgment are performed by applying a branch structure of a decision tree and accurately combining various characteristics, so that subjective and empirical deviations in a traditional diagnosis method are effectively avoided, and the diagnosis accuracy is improved. The accuracy of CVA diagnosis is remarkably improved, a child patient is helped to obtain correct treatment in time, and misdiagnosis and missed diagnosis can be effectively reduced.
Owner:JILIN ACAD OF TRADITIONAL CHINESE MEDICINE

Agonistic anti-tumor necrosis factor receptor 2 antibodies

The invention provides agonistic TNFR2 antibodies and antigen-binding fragments thereof and encompasses the use of these antibodies as therapeutics to promote the proliferation of regulatory T cells (T-reg) for the treatment of immunological diseases. Antibodies of the invention can be used to potentiate the T-reg-mediated deactivation of self- and allergen-reactive T- and B-lymphocytes, and can thus be used to treat a wide variety of indications, including autoimmune diseases, allergic reactions, asthma, graft-versus-host disease, and allograft rejection, among others.
Owner:THE GENERAL HOSPITAL CORP

Application of APE1 inhibitor in preparation of medicine for treating asthma

PendingCN119097712APromote type II immune mechanismPromote productionOrganic active ingredientsRespiratory disorderLung pathologyTherapeutic effect
The invention belongs to the field of small molecule compound medicines, and relates to application of an APE1 inhibitor in preparation of a medicine for treating asthma. The invention provides a novel treatment strategy of asthma, discovers a new target APE1 for treating asthma, realizes an effective treatment effect on asthma by using an APE1 inhibitor C10 compound, can remarkably inhibit the inflammatory cell activity such as mast cells, eosinophilic granulocytes and lymphocytes of asthma, and can remarkably inhibit the inflammatory cell activity of mice lung pathology observation. The C10 compound disclosed by the invention has obvious relieving and relieving effects on lung pathological changes of asthma mice, so that the C10 compound can be clinically used for preventing or treating asthma, and has the industrial advantages of small molecular weight and simple synthesis process.
Owner:SHANDONG UNIV QILU HOSPITAL